SLC25A16 (Gene)

Organism:

Homo sapiens

Synonyms:D10S105E, ENTREZ:8034, GDA, GDC, HGNC:10986, HGT.1, MIM:139080, ML7, NM_001324312, NM_001324313, NM_001324314, NM_001324315, NM_001324317, NM_152707, NP_001311241, NP_001311242, NP_001311243, NP_001311244, NP_001311246, NP_689920, NR_136737, SLC25A16, hML7, solute carrier family 25 member 16

Omim:OMIM:139080

Id:ENSG00000122912

Hgnc:HGNC:10986

Entrez:8034

Ensembl:ENSG00000122912

Description:solute carrier family 25 member 16

This gene encodes a protein that contains three tandemly repeated mitochondrial carrier protein domains. The encoded protein is localized in the inner membrane and facilitates the rapid transport and exchange of molecules between the cytosol and the mitochondrial matrix space. This gene has a possible role in Graves' disease. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View SLC25A16's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with SLC25A16.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using SLC25A16.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for SLC25A16.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with SLC25A16.

Results found

Linked to

	Label	Description
	GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE102757 1 V 0 PANOBINOSTAT MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE229973 3 V 2 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE255432 7 V 3 IMEGLIMIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE145195 PPP2R3B overexpression 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE228430 FABP5 inhibition Huh-7 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE163862 2 V 3 CISPLATIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158632 3 V 4 OXYQUINOLINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE228106 3 V 5 PACLITAXEL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE102757 1 V 0 PANOBINOSTAT MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE229973 3 V 2 CISPLATIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE255432 7 V 3 IMEGLIMIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE145195 PPP2R3B overexpression 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE228430 FABP5 inhibition Huh-7 2 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE163862 2 V 3 CISPLATIN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE158632 3 V 4 OXYQUINOLINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE228106 3 V 5 PACLITAXEL HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.